| Assay ID | Title | Year | Journal | Article |
|---|
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1498465 | Displacement of [3H]RTX from human TRPV1 expressed in HEK293 cell membranes after 60 mins by scintillation counting method | 2018 | Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
| Design, synthesis, and biological evaluation of novel biphenyl-4-carboxamide derivatives as orally available TRPV1 antagonists. |
| AID265492 | Volume of distribution in dog | 2006 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
| Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. |
| AID1904700 | Antagonist activity at human TRPV1 expressed in CHO cells assessed as inhibition of capsaicin-induced Ca2+ influx incubated for 30 mins by FLIPR method | 2022 | European journal of medicinal chemistry, Apr-05, Volume: 233 | Discovery of (S)-N-(3-isopropylphenyl)-2-(5-phenylthiazol-2-yl)pyrrolidine-1-carboxamide as potent and brain-penetrant TRPV1 antagonist. |
| AID265503 | Blockade of pH activated human TRPV1 at 1 uM | 2006 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
| Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. |
| AID265491 | Volume of distribution in guinea pig | 2006 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
| Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. |
| AID265488 | Clearance in guinea pig | 2006 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
| Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. |
| AID265485 | Intrinsic clearance in guinea pig liver microsomes | 2006 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
| Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. |
| AID265489 | Clearance in dog | 2006 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
| Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. |
| AID1904699 | Antagonist activity at human TRPV1 expressed in CHO cells assessed as inhibition of capsaicin-induced Ca2+ influx at 10 uM incubated for 30 mins by FLIPR method | 2022 | European journal of medicinal chemistry, Apr-05, Volume: 233 | Discovery of (S)-N-(3-isopropylphenyl)-2-(5-phenylthiazol-2-yl)pyrrolidine-1-carboxamide as potent and brain-penetrant TRPV1 antagonist. |
| AID265486 | Intrinsic clearance in dog liver microsomes | 2006 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
| Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. |
| AID265504 | Activity against capsaicin-induced secondary hyperalgesia assessed as reversal of allodynia in rat at 10 mg/kg, po after 2 hrs | 2006 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
| Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. |
| AID1904704 | Antinociceptive activity against thermal-induced nociception mouse model assessed as increase in tail withdrawal latency at 10 mg/kg, ip measured after 30 mins by tail flick test | 2022 | European journal of medicinal chemistry, Apr-05, Volume: 233 | Discovery of (S)-N-(3-isopropylphenyl)-2-(5-phenylthiazol-2-yl)pyrrolidine-1-carboxamide as potent and brain-penetrant TRPV1 antagonist. |
| AID265500 | Solubility in stimulated gastric fluid | 2006 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
| Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. |
| AID265502 | Blockade of heat activated human TRPV1 at 1 uM | 2006 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
| Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. |
| AID265484 | Antagonist activity against capsaicin-mediated activation of dog TRPV1 by FLIPR | 2006 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
| Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. |
| AID265505 | Activity against capsaicin-induced secondary hyperalgesia assessed as reversal of allodynia in rat at 30 mg/kg, po after 2 hrs | 2006 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
| Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. |
| AID265490 | Volume of distribution in rat | 2006 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
| Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. |
| AID265497 | Bioavailability in guinea pig at 1 mg/kg, po | 2006 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
| Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. |
| AID1904734 | Antagonist activity against human TRPM8 expressed in HEK293 cells assessed as inhibition of methanol-gated currents by whole cell patch clamp electrophysiology | 2022 | European journal of medicinal chemistry, Apr-05, Volume: 233 | Discovery of (S)-N-(3-isopropylphenyl)-2-(5-phenylthiazol-2-yl)pyrrolidine-1-carboxamide as potent and brain-penetrant TRPV1 antagonist. |
| AID265480 | Antagonist activity against capsaicin-mediated activation of rat TRPV1 by FLIPR | 2006 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
| Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. |
| AID1904701 | Antagonist activity at human TRPV1 expressed in CHO cells assessed as low pH-induced Ca2+ influx at 10 uM incubated for 30 mins at pH 5 by FLIPR method | 2022 | European journal of medicinal chemistry, Apr-05, Volume: 233 | Discovery of (S)-N-(3-isopropylphenyl)-2-(5-phenylthiazol-2-yl)pyrrolidine-1-carboxamide as potent and brain-penetrant TRPV1 antagonist. |
| AID1904708 | Toxicity in rat assessed as increase in body temperature at 30 mg/kg, po measured for 180 mins by electric probe thermometer analysis | 2022 | European journal of medicinal chemistry, Apr-05, Volume: 233 | Discovery of (S)-N-(3-isopropylphenyl)-2-(5-phenylthiazol-2-yl)pyrrolidine-1-carboxamide as potent and brain-penetrant TRPV1 antagonist. |
| AID265493 | Half life in rat | 2006 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
| Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. |
| AID265494 | Half life in guinea pig | 2006 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
| Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. |
| AID265506 | Activity against adjuvant-induced arthritis assessed as reversal of allodynia in guinea pig at 10 mg/kg, po | 2006 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
| Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. |
| AID1904703 | Antinociceptive activity in mouse assessed as reduction in acetic acid induced writhing response at 10 mg/kg, ip administered 30 mins prior to acetic acid administration and measured every 15 mins by abdominal constriction test | 2022 | European journal of medicinal chemistry, Apr-05, Volume: 233 | Discovery of (S)-N-(3-isopropylphenyl)-2-(5-phenylthiazol-2-yl)pyrrolidine-1-carboxamide as potent and brain-penetrant TRPV1 antagonist. |
| AID1904702 | Analgesic activity against capsaicin-induced pain mouse model assessed as reduction in time spent on foot licking behaviour at 10 mg/kg, ip administered 30 mins prior to capsaicin stimulation and measured after 5 mins | 2022 | European journal of medicinal chemistry, Apr-05, Volume: 233 | Discovery of (S)-N-(3-isopropylphenyl)-2-(5-phenylthiazol-2-yl)pyrrolidine-1-carboxamide as potent and brain-penetrant TRPV1 antagonist. |
| AID265498 | Bioavailability in dog at 3 mg/kg, po | 2006 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
| Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. |
| AID265483 | Antagonist activity against capsaicin-mediated activation of guinea pig TRPV1 by FLIPR | 2006 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
| Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. |
| AID265481 | Intrinsic clearance in rat liver microsomes | 2006 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
| Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. |
| AID472857 | Inhibition of rat TRPV1 | 2010 | Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8
| Discovery of novel 6,6-heterocycles as transient receptor potential vanilloid (TRPV1) antagonists. |
| AID265496 | Bioavailability in rat at 3 mg/kg, po | 2006 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
| Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. |
| AID265501 | Inhibition of capsaicin-mediated activation of human TRPV1 in HEK293 cells at 1 uM by patch clamp method | 2006 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
| Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. |
| AID265487 | Clearance in rat | 2006 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
| Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. |
| AID1904726 | Ratio of drug level in brain to plasma in rat at 10 mg/kg, iv measured after 0.5 hrs by HPLC analysis | 2022 | European journal of medicinal chemistry, Apr-05, Volume: 233 | Discovery of (S)-N-(3-isopropylphenyl)-2-(5-phenylthiazol-2-yl)pyrrolidine-1-carboxamide as potent and brain-penetrant TRPV1 antagonist. |
| AID265495 | Half life in dog | 2006 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
| Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. |
| AID1868420 | Analgesic activity in C57BL/6 mouse model of capsaicin-induced allodynia assessed as reduction on foot licking pain response at 40 mg/kg,po measured after 5 mins | 2022 | European journal of medicinal chemistry, Jul-05, Volume: 237 | Optimization of 4-arylthiophene-3-carboxylic acid derivatives as inhibitors of ANO1: Lead optimization studies toward their analgesic efficacy for inflammatory pain. |
| AID1346617 | Human TRPV1 (Transient Receptor Potential channels) | 2007 | The Journal of pharmacology and experimental therapeutics, Jun, Volume: 321, Issue:3
| Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor. |
| AID1797978 | FLIPR (Fluorescence Imaging Plate Reader)-Based Ca2+ Assay from Article 10.1016/j.bmcl.2006.03.030: \\Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development.\\ | 2006 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
| Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |